Alembic Pharmaceuticals Limited
NSE:APLLTD.NS
896.55 (INR) • At close May 9, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) INR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 62,286.3 | 56,526.2 | 52,317.9 | 52,762.2 | 44,919.7 | 38,066.1 | 30,350.4 | 30,300.6 | 30,549.732 | 20,099.688 | 18,201.149 | 14,931.432 | 14,663.874 | 11,989.875 |
| Cost of Revenue
| 39,598 | 17,088.2 | 17,231.9 | 15,212.7 | 13,141.1 | 11,933.8 | 10,621.3 | 10,372.7 | 8,425.678 | 7,582.528 | 7,591.498 | 7,166.252 | 7,079.202 | 6,523.581 |
| Gross Profit
| 22,688.3 | 39,438 | 35,086 | 37,549.5 | 31,778.6 | 26,132.3 | 19,729.1 | 19,927.9 | 22,124.054 | 12,517.16 | 10,609.651 | 7,765.18 | 7,584.672 | 5,466.294 |
| Gross Profit Ratio
| 0.364 | 0.698 | 0.671 | 0.712 | 0.707 | 0.686 | 0.65 | 0.658 | 0.724 | 0.623 | 0.583 | 0.52 | 0.517 | 0.456 |
| Reseach & Development Expenses
| 4,385.6 | 290.7 | 505.9 | 253.8 | 426.4 | 302.7 | 368.6 | 982 | 3,070.629 | 1,216.226 | 1,164.322 | 736.328 | 585.822 | 471.318 |
| General & Administrative Expenses
| 2,519.7 | 2,410.5 | 2,109.8 | 2,086.6 | 1,551.2 | 1,350.7 | 1,102 | 1,448.7 | 517.355 | 423.505 | 331.937 | 205.138 | 119.483 | 0 |
| Selling & Marketing Expenses
| 9,968.8 | 9,523 | 8,903.8 | 6,962.5 | 5,311.9 | 5,900.4 | 3,802.3 | 3,931.4 | 2,736.712 | 2,446.879 | 1,940.321 | 1,548.52 | 1,082.075 | 1,136.501 |
| SG&A
| 12,488.5 | 11,933.5 | 11,013.6 | 9,049.1 | 6,863.1 | 7,251.1 | 4,904.3 | 5,380.1 | 3,254.067 | 2,870.384 | 2,272.258 | 1,753.658 | 1,201.558 | 1,136.501 |
| Other Expenses
| -181.5 | 27.4 | 1.3 | 2 | 0.2 | 2.3 | 0.3 | 2.5 | 6,737.51 | 17.32 | 10.042 | 3,318.01 | 4.372 | 2,551.155 |
| Operating Expenses
| 15,869.7 | 35,108.9 | 29,160 | 24,581.1 | 20,669 | 18,558.1 | 14,630.6 | 14,535.9 | 12,766.553 | 8,985.308 | 7,399.866 | 5,624.935 | 5,651.539 | 4,158.974 |
| Operating Income
| 5,758.1 | 4,377.8 | 5,874.7 | 12,968.4 | 11,114.1 | 7,413.2 | 5,098.5 | 5,392 | 9,357.501 | 3,531.852 | 3,209.785 | 2,140.245 | 1,933.133 | 1,307.32 |
| Operating Income Ratio
| 0.092 | 0.077 | 0.112 | 0.246 | 0.247 | 0.195 | 0.168 | 0.178 | 0.306 | 0.176 | 0.176 | 0.143 | 0.132 | 0.109 |
| Total Other Income Expenses Net
| 560.2 | -338 | -12,107.7 | -9,634.8 | -1,111.4 | -45.1 | 314.1 | -107.8 | -0.9 | 58.863 | -103.673 | -76.703 | -313.51 | -247.401 |
| Income Before Tax
| 6,318.3 | 3,545.9 | 6,201.1 | 13,680.8 | 9,998.2 | 7,493.2 | 5,412.7 | 5,253.6 | 9,356.019 | 3,590.715 | 3,106.112 | 2,063.542 | 1,609.824 | 1,068.433 |
| Income Before Tax Ratio
| 0.101 | 0.063 | 0.119 | 0.259 | 0.223 | 0.197 | 0.178 | 0.173 | 0.306 | 0.179 | 0.171 | 0.138 | 0.11 | 0.089 |
| Income Tax Expense
| 160 | 126.1 | 1,044.6 | 2,533.2 | 1,991.8 | 1,567.5 | 1,203.5 | 1,221.9 | 2,160.148 | 763.491 | 751.028 | 410.995 | 308.498 | 214.557 |
| Net Income
| 6,158.2 | 3,419.9 | 5,209.4 | 11,465 | 8,288.2 | 5,843.7 | 4,126.3 | 4,031.7 | 7,194.368 | 2,829.246 | 2,355.084 | 1,652.547 | 1,301.326 | 853.876 |
| Net Income Ratio
| 0.099 | 0.061 | 0.1 | 0.217 | 0.185 | 0.154 | 0.136 | 0.133 | 0.235 | 0.141 | 0.129 | 0.111 | 0.089 | 0.071 |
| EPS
| 31.33 | 17.4 | 26.5 | 59.18 | 43.97 | 31 | 21.89 | 21.39 | 38.19 | 15.01 | 12.49 | 8.77 | 6.9 | 4.53 |
| EPS Diluted
| 31.33 | 17.4 | 26.5 | 59.18 | 43.97 | 31 | 21.89 | 21.39 | 38.19 | 15.01 | 12.49 | 8.77 | 6.9 | 4.53 |
| EBITDA
| 9,616.7 | 7,111.1 | 9,246.2 | 15,675.7 | 11,843 | 8,829.6 | 6,501.3 | 6,214.1 | 10,033.1 | 3,993.303 | 3,624.701 | 2,653.048 | 2,321.806 | 1,603.185 |
| EBITDA Ratio
| 0.154 | 0.126 | 0.177 | 0.297 | 0.264 | 0.232 | 0.214 | 0.205 | 0.328 | 0.199 | 0.199 | 0.178 | 0.158 | 0.134 |